Glucagon-like peptide-1 (GLP-1) reduces mortality and improves lung function in a model of experimental obstructive lung disease in female mice
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
The incretin hormone glucagon-like peptide-1 (GLP-1) is an important insulin secretagogue and GLP-1 analogues are used for the treatment of type 2 diabetes. GLP-1 displays anti-inflammatory and surfactant releasing effects. Thus, we hypothesize that treatment with GLP-1 analogues will improve pulmonary function in a mouse model of obstructive lung disease. Female mice were sensitized with injected ovalbumin and treated with GLP-1 receptor (GLP-1R) agonists. Exacerbation was induced with inhalations of ovalbumin and lipopolysaccharide. Lung function was evaluated with measurement of enhanced pause (Penh) in a whole body plethysmograph. mRNA levels of GLP-1R, surfactants (SFTPs), and a number of inflammatory markers were measured. GLP-1R was highly expressed in lung tissue. Mice treated with GLP-1R agonists had a noticeably better clinical appearance than the control group. Penh increased dramatically at day 17 in all control mice but the increase was significantly less in the groups of GLP-1R agonist treated mice (p
Originalsprog | Engelsk |
---|---|
Tidsskrift | Endocrinology |
Vol/bind | 154 |
Udgave nummer | 12 |
Sider (fra-til) | 4503-4511 |
Antal sider | 9 |
ISSN | 0013-7227 |
DOI | |
Status | Udgivet - 2013 |
ID: 57754734